Xenetic Biosciences, Inc. (XBIO)
After hours:
| Previous Close | 3.7300 |
| Open | 3.8100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.6200 - 3.8400 |
| 52 Week Range | 2.7800 - 5.2000 |
| Volume | |
| Avg. Volume | 17,053 |
| Market Cap | 5.598M |
| Beta (5Y Monthly) | 2.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.0600 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREXenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
FRAMINGHAM, MA / ACCESSWIRE / October 22, 2024 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, ...
ACCESSWIREXenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Xenetic to supply recombinant DNase I to Tokyo Medical University for evaluation as a treatment of Ewing sarcoma in unique preclinical model FRAMINGHAM, MA / ACCESSWIRE / October 17, 2024 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the ...
ACCESSWIREXenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today ...
